Syros Pharmaceuticals, Inc. (SYRS)
NASDAQ: SYRS · IEX Real-Time Price · USD
5.00
+0.07 (1.42%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Syros Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for SYRS stock have an average target of 14, with a low estimate of 13 and a high estimate of 15. The average target predicts an increase of 180.00% from the current stock price of 5.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SYRS stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 3 | 3 | 3 | 2 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 3 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +200.00% | Jun 26, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +200.00% | May 15, 2024 |
Piper Sandler | Piper Sandler | Buy Reiterates $13 | Buy | Reiterates | $13 | +160.00% | Apr 3, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +200.00% | Apr 1, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $11 → $7 | Buy | Maintains | $11 → $7 | +40.00% | Oct 3, 2023 |
Financial Forecast
Revenue This Year
1.39M
from 9.94M
Decreased by -86.04%
Revenue Next Year
32.72M
from 1.39M
Increased by 2,259.19%
EPS This Year
-2.48
from -5.81
EPS Next Year
-2.65
from -2.48
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 5.6M | 136.9M | 345.7M | 757.5M | 1.0B |
Avg | 1.4M | 32.7M | 154.2M | 342.3M | 547.3M |
Low | n/a | n/a | 38.5M | 78.7M | 230.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -44.0% | 9,771.7% | 956.4% | 391.3% | 203.6% |
Avg | -86.0% | 2,259.2% | 371.2% | 122.0% | 59.9% |
Low | - | - | 17.7% | -49.0% | -32.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.32 | -0.81 | 1.70 | -1.56 | 1.50 |
Avg | -2.48 | -2.65 | -0.81 | -1.52 | 1.46 |
Low | -2.62 | -4.03 | -2.31 | -1.46 | 1.40 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.